Comparative Efficacy and Safety of Atypical and Conventional Antipsychotic Drugs in First-Episode Psychosis: A Randomized, Double-Blind Trial of Olanzapine Versus Haloperidol

American Journal of Psychiatry - Tập 160 Số 8 - Trang 1396-1404 - 2003
Jeffrey A. Lieberman1, Gary D. Tollefson, Mauricio Tohen, Alan I. Green, Raquel E. Gur, René S. Kahn, Joseph P. McEvoy, Diana O. Perkins, Tonmoy Sharma, Robert B. Zipursky, Hank Wei, Robert M. Hamer
1Department of Psychiatry, University of North Carolina School of Medicine, NC 27599-7160, USA. [email protected]

Tóm tắt

Từ khóa


Tài liệu tham khảo

National Institute of Mental Health Psychopharmacology Service Center Collaborative Study Group: Phenothiazine treatment in acute schizophrenia. Arch Gen Psychiatry 1964; 10:246–261

Hegarty JD, Baldessarini RJ, Tohen M, Waternaux C, Oepen G: One hundred years of schizophrenia: a meta-analysis of the outcome literature. Am J Psychiatry 1994; 151:1409–1416

May PR, Tuma AH, Dixon WJ, Yale C, Thiele DA, Kraude WH: Schizophrenia: a follow-up study of the results of five forms of treatment. Arch Gen Psychiatry 1981; 38:776–784

Sheitman BB, Lee H, Strous R, Lieberman JA: The evaluation and treatment of first-episode psychoses. Schizophr Bull 1997; 23:653–661

Robinson DG, Woerner MG, Alvir JMJ, Geisler S, Koreen A, Sheitman B, Chakos M, Mayerhoff D, Bilder R, Goldman R, Lieberman JA: Predictors of treatment response from a first episode of schizophrenia or schizoaffective disorder. Am J Psychiatry 1999; 156:544–549

Lieberman JA, Sheitman B, Chakos M, Robinson D, Schooler N, Keith S: The development of treatment resistance in patients with schizophrenia: a clinical and pathophysiological perspective. J Clin Psychopharmacol 1998; 18:20S-24S

Chatterjee A, Chakos M, Koreen A, Geisler S, Sheitman B, Woerner M, Kane JM, Alvir J, Lieberman JA: Prevalence and clinical correlates of extrapyramidal signs and spontaneous dyskinesia in never-medicated schizophrenic patients. Am J Psychiatry 1995; 152:1724–1729

Chakos MH, Alvir JM, Woerner MG, Koreen A, Geisler S, Mayerhoff D, Sobel S, Kane JM, Borenstein M, Lieberman JA: Incidence and correlates of tardive dyskinesia in first episode of schizophrenia. Arch Gen Psychiatry 1996; 53:313–319

McEvoy JP, Hogarty GE, Steingard S: Optimal dose of neuroleptic in acute schizophrenia: a controlled study of the neuroleptic threshold and higher haloperidol dose. Arch Gen Psychiatry 1991; 48:739–745

Kane JM, Rifkin A, Woerner M, Reardon G, Sarantakos S, Schiebel D, Ramos-Lorenzi J: Low-dose neuroleptic treatment of outpatient schizophrenics, I: preliminary results for relapse rates. Arch Gen Psychiatry 1983; 40:893–896

Crow TJ, MacMillan JF, Johnson AL, Johnstone EC: A randomised controlled trial of prophylactic neuroleptic treatment. Br J Psychiatry 1986; 148:120–127

Tohen M, Stoll AL, Strakowski SM, Faedda GL, Mayer PV, Goodwin DC, Kolbrener ML, Madigan AM: The McLean first-episode psychosis project: six-month recovery and recurrence outcome. Schizophr Bull 1992; 18:172–185

Gitlin M, Nuechterlein K, Subotnik KL, Ventura J, Mintz J, Fogelson DL, Bratzokis G, Aravagiri M: Clinical outcome following neuroleptic discontinuation in patients with remitted recent-onset schizophrenia. Am J Psychiatry 2001; 158:1835–1842

Robinson D, Woerner MG, Alvir JM, Bilder R, Goldman R, Geisler S, Koreen A, Sheitman B, Chakos M, Mayerhoff D, Lieberman JA: Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Arch Gen Psychiatry 1999; 56:241–247

Kinon BJ, Lieberman JA: Mechanisms of action of atypical antipsychotic drugs: a critical analysis. Psychopharmacology (Berl) 1996; 124:2–34

Leucht S, Pitschel-Walz G, Abraham D, Kissling W: Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo: a meta-analysis of randomized controlled trials. Schizophr Res 1999; 35:51–68

Geddes J, Freemantle N, Harrison P, Bebbington P: Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. Br Med J 2000; 321:1371–1376

Chakos M, Lieberman J, Hoffman E, Bradford D, Sheitman B: Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: a review and meta-analysis of randomized trials. Am J Psychiatry 2001; 158:518–526

Emsley RA (Risperidone Working Group): Risperidone in the treatment of first-episode psychotic patients: a double-blind multicenter study. Schizophr Bull 1999; 25:721–729

Sanger TM, Lieberman JA, Tohen M, Grundy S, Beasley C Jr, Tollefson GD: Olanzapine versus haloperidol treatment in first-episode psychosis. Am J Psychiatry 1999; 156:79–87

Lieberman JA: Atypical antipsychotic drugs as a first-line treatment of schizophrenia: rationale and hypothesis. J Clin Psychiatry 1996; 57(suppl 11):68–71

Green AI, Schildkraut JJ: Should clozapine be a first-line treatment for schizophrenia? the rationale for a double-blind clinical trial in first-episode patients. Harv Rev Psychiatry 1995; 3:1–9

Kay SR, Fiszbein A, Opler LA: The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull 1987; 13:261–276

Montgomery SA, Åsberg M: A new depression scale designed to be sensitive to change. Br J Psychiatry 1979; 134:382–389

Simpson GM, Angus JWS: A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl 1970; 212:11–19

Barnes TRE: A rating scale for drug-induced akathisia. Br J Psychiatry 1989; 154:672–676

Lieberman JA, Phillips M, Gu H, Stroup S, Zhang P, Kong L, Ji Z, Koch G, Hamer RM: Atypical and conventional antipsychotic drugs in treatment-naive first-episode schizophrenia: a 52-week randomized trial of clozapine vs chlorpromazine. Neuropsychopharmacology 2003; 28:995–1003

Wahlbeck K, Tuunainen A, Ahokas A, Leucht S: Dropout rates in randomised antipsychotic drug trials. Psychopharmacology (Berl) 2001; 155:230–233

Keefe RS, Seidman LJ, Christensen BK, Yurgelun-Todd DA, Lewine RR, Sitskoorn MM, Lieberman JA: Treatment of neurocognitive deficits with olanzapine or low-dose haloperidol in first episode psychosis, in Abstracts of the VIII International Congress on Schizophrenia Research. Schizophrenia Research 2001; 49(1–2) [Suppl]:234

Csernansky JG, Mahmoud R, Brenner R (Risperidone-USA-79 Study Group): A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. N Engl J Med 2002; 346:16–22

Meltzer HY, Alphs L, Green AI, Altamura AC, Anand R, Bertoldi A, Bourgeois M, Chouinard G, Islam MZ, Kane J, Krishnan R, Lindenmayer JP, Potkin S: Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT). Arch Gen Psychiatry 2003; 60:82–91